Andrew Bottomley on Muck Rack

Andrew Bottomley

Toronto
As seen in: MSN Canada, Nature, JAMA (The Journal of the American Medical Association), Sportsnet Canada, The Lancet, CKWX-AM (Vancouver, BC), Golf Canada, European Journal of Cancer, Lung Cancer, Busk Music
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Andrew

Contact Andrew, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesothelioma - Scientific Reports

|
By Charles S. Cleeland, Karen Keating, Jonathan M. Siegel, Christoph Gerlinger, Jeff Sloan, Amylou C. Dueck, Andrew Bottomley, Xin Wang, Loretta Williams, Brian Cuffel, Cem Elbi
| Nature
Abstract We developed a composite symptom score (CSS) representing disease-related symptom burden over time in patients with malignant pleural mesothelioma (MPM). Longitudinal data were collected from an open-label Phase IIB study in which 239 patients completed the validated MD Anderson Symptom Inventory for MPM (MDASI-MPM). A blinded, independent review committee of external patient-reported outcomes experts advised on MDASI-MPM symptoms to include in the CSS.
Open in Who Shared Issue with article?

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

|
By Andrew Bottomley, EORTC Headquarters, Corneel Coens, Justyna Mierzynska
| The Lancet
Summary Background The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with placebo (hazard ratio 0·57 [98·4% CI 0·43–0·74]; p<0·0001). This study reports the results from the health-related quality-of-life (HRQOL) exploratory endpoint.
Open in Who Shared Issue with article?

Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials

|
By Vrije Universiteit Amsterdam, Andrew Bottomley, European Organisation, Ivan Caramanna
| European Journal of Cancer
Highlights • Neurocognitive deficits have been reported to hamper cognitive awareness. • Awareness is measured as the concordance of neurocognitive functioning and complaints. • Patients were divided in impaired and intact based on their neurocognitive performance. • Neurocognitively impaired patients reported more complaints than unimpaired ones. • Neurocognitive impairment in patients with high grade glioma does not preclude cognitive awareness.
Open in Who Shared Issue with article?
See all 386 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Andrew

Contact Andrew, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified